MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.50 and traded as high as $1.62. MediciNova shares last traded at $1.56, with a volume of 16,286 shares changing hands.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on MediciNova in a research note on Thursday. They issued a "hold" rating for the company.
Get Our Latest Stock Report on MNOV
MediciNova Stock Up 0.6 %
The stock has a market capitalization of $77.01 million, a PE ratio of -9.81 and a beta of 0.77. The firm has a 50 day moving average price of $1.81 and a 200-day moving average price of $1.50.
MediciNova (NASDAQ:MNOV - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities analysts expect that MediciNova, Inc. will post -0.23 earnings per share for the current fiscal year.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
